Lamotrigine hydrate

Lamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al[1][2].

Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel

Signaling Pathways >> Autophagy >> Autophagy

Research Areas >> Neurological Disease

Lamotrigine hydrate inhibits Veratrine evoked release of glutamate and aspartate with ED50 values of 21 μM for both amino acids, but Lamotrigine hydrate is less potent in the inhibition of GABA release (ED50=44 μM. At concentrations up to 300 μM, LTG has no effect on patassium-evoked amino acid[1]. Lamotrigine hydrate is some five times less potent in the inhibition of Veratrine-evoked [3H]acetylcholine release (ED50=100 μM) than in glutamate or aspartate release[1].

Lamotrigine hydrate (IP, 30 min before pentylenetetrazol; 10 mg/kg, 15 mg/kg or 20 mg/kg) decreases the seizure intensity at the higher doses, it increases the latency to the first pentylenetetrazol-induced seizure in all studied doses compared with the controls[2].

[1]. M J Leach, et al. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. Sep-Oct 1986;27(5):490-7.

[2]. Damianka P Getova, et al. A study of the effects of lamotrigine on mice using two convulsive tests. Folia Med (Plovdiv). Apr-Jun 2011;53(2):57-62.